1. Home
  2. XBIT vs GANX Comparison

XBIT vs GANX Comparison

Compare XBIT & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

SELL

Current Price

$2.20

Market Cap

66.8M

Sector

Health Care

ML Signal

SELL

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

SELL

Current Price

$1.68

Market Cap

76.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
XBIT
GANX
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.8M
76.8M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
XBIT
GANX
Price
$2.20
$1.68
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $7.20
AVG Volume (30 Days)
25.8K
★ 441.1K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.46
EPS
N/A
★ N/A
Revenue
N/A
★ $55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
$30.47
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.09
$1.53
52 Week High
$3.44
$4.34

Technical Indicators

Market Signals
Indicator
XBIT
GANX
Relative Strength Index (RSI) 50.35 40.97
Support Level $2.19 $1.58
Resistance Level $2.48 $2.01
Average True Range (ATR) 0.03 0.10
MACD 0.01 -0.01
Stochastic Oscillator 70.00 20.09

Price Performance

Historical Comparison
XBIT
GANX

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: